Table 1.
Cohort characteristics at recruitment.
| Characteristic | Transplant Recipients (n = 135) | Controls (n=29) |
|---|---|---|
| Male gender | 92 (68.1) | 16 (55.2) |
| Caucasian ethnicity | 131 (97.0) | 29 (100) |
| Age (years) | 62.6 ± 10.8 | 74.9 ± 8.9 |
| >1 renal transplant | 25 (18.5) | NA |
| Body mass index (kg/m2) | 25.8 ± 4.7 | NA |
| Previous or current smoker | 52 (38.5) | NA |
| Cytomegalovirus (CMV) seropositive | 86 (63.7) | NA |
| Total HLA mismatch | 2.6 ± 1.5 | NA |
| Total duration of immunosuppression (months) | 244 ± 102 | NA |
| Time since most recent transplant (months) | 223 ± 99 | NA |
| eGFR at recruitment (mL/min/1.73m2) | 48.8 ± 19.1 | 70.0 ± 19.1 |
| eGFR at study end (mL/min/1.73m2) | 48.3 ± 20.8 | N/A |
| Induction therapy at most recent transplant None Thymoglobulin Alemtuzumab Basiliximab |
99 (73.3) 7 (5.2) 10 (7.4) 19 (14.1) |
NA |
| Immunosuppression use at recruitment Calcineurin inhibitor Azathioprine Mycophenolate mofetil Prednisolone Sirolimus |
107 (79.3) 89 (65.9) 22 (16.3) 46 (34.1) 13 (9.6) |
NA |
| Number of immunosuppressive agents at recruitment 1 2 3 |
17 (12.4) 98 (71.5) 22 (16.1) |
NA |
| History of previous non-keratinocyte malignancy | 16 (11.9) | NA |
| History of previous SCC | 59 (43.7) | 20 (68.9) |
Categorical values are provided as n (%) whilst continuous variables are reported as mean ± SD. ‘NA’ not assessed/applicable. Data was available for all participants.